Picture Berlin Partner Top News Tacalyx Extends Seed Round to €14m 650x100px
Document › Details

Adrenomed AG. (8/13/19). "Press Release: Adrenomed AG Takes Part in Four Upcoming Conferences". Hennigsdorf.

Organisations Organisation Adrenomed AG
  Organisation 2 University of Nijmegen (Radboud University)
Products Product Adrecizumab
  Product 2 Sachs Annual Biotech in Europe Forum 2019 Basel
Persons Person Hein, Frauke (Bico 202206– CEO of Scienion before MLDx GmbH + Adrenomed + BRAHMS + Brandenburg)
  Person 2 von Hummel, Julia (MC Services 201811)

Adrenomed AG, the vascular integrity company, announced today its participation at four upcoming conferences in Europe. Adrenomed representatives will be available for networking and one-to-one meetings at the following events:

Weimar Sepsis Update – Symposium

September 11th – 13th, 2019, Congress Centrum Neue Weimarhalle, Weimar, Germany
Adrenomed will co-host the lunch symposium “Beyond Standard of Care – New Perspectives on Vascular Integrity in Shock” on September 13th, 12:00 – 13:30 CET.

19th Annual Biotech in Europe Forum (Sachs Conference)

September 25th – 26th, 2019, Congress Center Basel, Switzerland
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will participate in the “Platform Technologies & Novel Therapeutics Panel” on September 25th, 10:45 CET.

European Business Development Conference (EBDC)

September 25th – 26th, 2019, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a “Spotlight Talk on Sepsis” on September 26th, 12:00 CET.

32nd European Society of Intensive Care Medicine (ESICM) LIVES

September 28th – October 2nd, 2019, CityCube, Berlin, Germany
Prof. Dr. Peter Pickkers, Radboud University, Department of Intensive Care, Nijmegen, The Netherlands, will give a presentation about “Adrenomedullin in sepsis, effect of the non-inhibitory antibody Adrecizumab”, session “Innovation in sepsis treatment”, on October 1st, 16:20 CET, room Stockholm.

About Adrenomed

Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.

Adrenomed AG


Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814

Media Inquiries
MC Services AG
Eva Bauer/Julia von Hummel
phone: +49 (0)89 21022880

Record changed: 2023-06-05


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Adrenomed AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top